Published in Nat Med on May 23, 2010
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature (2011) 5.27
Parkin mediates proteasome-dependent protein degradation and rupture of the outer mitochondrial membrane. J Biol Chem (2011) 2.99
Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci (2012) 2.35
Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci (2012) 1.95
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. PLoS Biol (2012) 1.80
Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med (2012) 1.75
Subjective Experiences of Speech and Language Therapy in Patients with Parkinson's Disease: A Pilot Study. Rehabil Res Pract (2015) 1.37
Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord (2012) 1.36
Integrating pathways of Parkinson's disease in a molecular interaction map. Mol Neurobiol (2013) 1.34
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev (2011) 1.29
Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A (2013) 1.24
Role of oxidative stress in Parkinson's disease. Exp Neurobiol (2013) 1.23
Novel microRNAs differentially expressed during aging in the mouse brain. PLoS One (2012) 1.20
Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci (2013) 1.18
Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord (2012) 1.13
The evolution of dopamine systems in chordates. Front Neuroanat (2011) 1.11
Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharmacol Toxicol (2014) 1.09
Oxidative stress and Parkinson's disease. Front Neuroanat (2015) 1.08
The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front Comput Neurosci (2013) 1.06
Sonic hedgehog maintains cellular and neurochemical homeostasis in the adult nigrostriatal circuit. Neuron (2012) 1.05
Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS One (2012) 1.04
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim Biophys Acta (2013) 1.04
The dopaminergic system in the aging brain of Drosophila. Front Neurosci (2010) 1.02
The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain (2012) 1.01
Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol (2013) 1.00
GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proc Natl Acad Sci U S A (2013) 0.99
Oxidative stress in genetic mouse models of Parkinson's disease. Oxid Med Cell Longev (2012) 0.98
Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases. CNS Neurol Disord Drug Targets (2013) 0.98
Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol (2013) 0.97
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson's disease. J Exp Med (2012) 0.96
Specificity and kinetics of alpha-synuclein binding to model membranes determined with fluorescent excited state intramolecular proton transfer (ESIPT) probe. J Biol Chem (2011) 0.94
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease. Proc Natl Acad Sci U S A (2015) 0.93
Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease? Front Cell Neurosci (2013) 0.93
miR-7 and miR-153 protect neurons against MPP(+)-induced cell death via upregulation of mTOR pathway. Front Cell Neurosci (2014) 0.93
Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res (2013) 0.93
Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J Cell Biochem (2012) 0.92
Insights on altered mitochondrial function and dynamics in the pathogenesis of neurodegeneration. Transl Neurodegener (2013) 0.92
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
Parkinson's disease as a result of aging. Aging Cell (2015) 0.92
Genetic modification of the association of paraquat and Parkinson's disease. Mov Disord (2012) 0.91
Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study. Schizophr Bull (2013) 0.91
Proteolytic activation of proapoptotic kinase protein kinase Cδ by tumor necrosis factor α death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation (2012) 0.91
α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol (2013) 0.91
Brainstem: neglected locus in neurodegenerative diseases. Front Neurol (2011) 0.90
Glycogen synthase kinase-3 inhibitors as potent therapeutic agents for the treatment of Parkinson disease. ACS Chem Neurosci (2012) 0.89
Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function. Neurobiol Dis (2012) 0.88
α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology (2013) 0.87
Transcription factors FOXA1 and FOXA2 maintain dopaminergic neuronal properties and control feeding behavior in adult mice. Proc Natl Acad Sci U S A (2015) 0.87
Inflammatory mediators as biomarkers in brain disorders. Inflammation (2014) 0.86
Inflammatory Pathways in Parkinson's Disease; A BNE Microarray Study. Parkinsons Dis (2012) 0.86
Treating Parkinson's disease in the 21st century: can stem cell transplantation compete? J Comp Neurol (2014) 0.86
DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: involvement of mitochondrial complex I assembly. PLoS One (2012) 0.86
Activation of D₂-like receptors in rat ventral tegmental area inhibits cocaine-reinstated drug-seeking behavior. Eur J Neurosci (2011) 0.85
Microtubule destabilization is shared by genetic and idiopathic Parkinson's disease patient fibroblasts. PLoS One (2012) 0.85
Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra. PLoS Genet (2014) 0.84
Timing of deep brain stimulation in Parkinson disease: a need for reappraisal? Ann Neurol (2013) 0.84
An association study between Heme oxygenase-1 genetic variants and Parkinson's disease. Front Cell Neurosci (2014) 0.84
Regulation of cocaine-induced reinstatement by group II metabotropic glutamate receptors in the ventral tegmental area. Psychopharmacology (Berl) (2011) 0.84
Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease. Parkinsonism Relat Disord (2013) 0.84
Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Front Neurosci (2015) 0.84
Past, present, and future of the pathophysiological model of the Basal Ganglia. Front Neuroanat (2011) 0.83
Association of Parkinson's Disease and Its Subtypes with Agricultural Pesticide Exposures in Men: A Case-Control Study in France. Environ Health Perspect (2015) 0.83
Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration. Neurotoxicology (2012) 0.83
Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. Front Neurosci (2013) 0.83
Natural toxins implicated in the development of Parkinson's disease. Ther Adv Neurol Disord (2011) 0.83
The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys. J Pharmacol Exp Ther (2014) 0.83
Silymarin improved 6-OHDA-induced motor impairment in hemi-parkisonian rats: behavioral and molecular study. Daru (2014) 0.82
Role for the nicotinic cholinergic system in movement disorders; therapeutic implications. Pharmacol Ther (2014) 0.82
Interplay between sumoylation and phosphorylation for protection against α-synuclein inclusions. J Biol Chem (2014) 0.82
Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease. Age (Dordr) (2011) 0.82
Hunting for the function of orphan GPCRs - beyond the search for the endogenous ligand. Br J Pharmacol (2014) 0.82
Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor. Hum Brain Mapp (2016) 0.80
Parkin in the regulation of fat uptake and mitochondrial biology: emerging links in the pathophysiology of Parkinson's disease. Curr Opin Lipidol (2012) 0.80
Real-time chemical measurements of dopamine release in the brain. Methods Mol Biol (2013) 0.80
Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease. PLoS One (2011) 0.80
Deep brain stimulation modulates nonsense-mediated RNA decay in Parkinson's patients leukocytes. BMC Genomics (2013) 0.80
The degeneration and replacement of dopamine cells in Parkinson's disease: the role of aging. Front Neuroanat (2014) 0.80
Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu₄. ACS Comb Sci (2011) 0.80
Heterogeneous intrastriatal pattern of proteins regulating axon growth in normal adult human brain. Neurobiol Dis (2010) 0.80
Parkinson disease: Parkinson disease clinical subtypes and their implications. Nat Rev Neurol (2011) 0.80
Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease. J Neuroinflammation (2012) 0.80
Unraveling the characteristics of microRNA regulation in the developmental and aging process of the human brain. BMC Med Genomics (2013) 0.80
Copper and copper proteins in Parkinson's disease. Oxid Med Cell Longev (2014) 0.80
Activity-dependent regulation of NMDA receptors in substantia nigra dopaminergic neurones. J Physiol (2013) 0.79
Mitomycin-treated undifferentiated embryonic stem cells as a safe and effective therapeutic strategy in a mouse model of Parkinson's disease. Front Cell Neurosci (2015) 0.79
BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neuroscience (2011) 0.79
Modulation of the glutamatergic transmission by Dopamine: a focus on Parkinson, Huntington and Addiction diseases. Front Cell Neurosci (2015) 0.79
Transcranial magnetic stimulation to understand pathophysiology and as potential treatment for neurodegenerative diseases. Transl Neurodegener (2015) 0.79
Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease. Neurobiol Dis (2016) 0.79
Photobiomodulation Suppresses Alpha-Synuclein-Induced Toxicity in an AAV-Based Rat Genetic Model of Parkinson's Disease. PLoS One (2015) 0.79
Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease. Protoplasma (2016) 0.78
Being too inclusive about synuclein inclusions. Nat Med (2010) 0.78
Differential Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on Motor Behavior and Dopamine Levels at Brain Regions in Three Different Mouse Strains. Korean J Physiol Pharmacol (2013) 0.78
Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats. Adv Pharm Bull (2015) 0.78
Tryptophan hydroxylase 2 aggregates through disulfide cross-linking upon oxidation: possible link to serotonin deficits and non-motor symptoms in Parkinson's disease. J Neurochem (2010) 0.78
Inhibitory and excitatory neuromodulation by hydrogen peroxide: translating energetics to information. J Physiol (2015) 0.78
Systems-based analyses of brain regions functionally impacted in Parkinson's disease reveals underlying causal mechanisms. PLoS One (2014) 0.78
Iron in neurodegenerative disorders of protein misfolding: a case of prion disorders and Parkinson's disease. Antioxid Redox Signal (2014) 0.78
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell (2009) 13.02
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science (2004) 8.71
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 7.01
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Parkinson's disease. Lancet (2009) 6.60
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature (2007) 5.03
Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet (2006) 4.61
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet (2010) 4.26
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A (2002) 4.20
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain (2009) 4.01
Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93
Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci (2009) 3.68
Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med (1995) 3.64
Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol (2003) 3.57
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol (2005) 3.31
Progress toward the clinical application of patient-specific pluripotent stem cells. J Clin Invest (2010) 3.12
Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron (2009) 3.11
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
Hypocretin (orexin) cell loss in Parkinson's disease. Brain (2007) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med (2008) 2.80
Genetic determinants of hair color and Parkinson's disease risk. Ann Neurol (2009) 2.78
A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord (2005) 2.70
Loss of parkin or PINK1 function increases Drp1-dependent mitochondrial fragmentation. J Biol Chem (2009) 2.64
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
Changes in network activity with the progression of Parkinson's disease. Brain (2007) 2.46
A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol (2008) 2.44
Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci (2007) 2.39
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol (2008) 2.26
The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol (2006) 2.23
Behavioral improvement in a primate Parkinson's model is associated with multiple homeostatic effects of human neural stem cells. Proc Natl Acad Sci U S A (2007) 2.19
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol (2004) 2.11
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol (2009) 2.00
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98
A clinico-pathological study of subtypes in Parkinson's disease. Brain (2009) 1.91
alpha-Synuclein and neuronal cell death. Mol Neurodegener (2009) 1.85
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain (2002) 1.85
Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology (2005) 1.82
Parkin-induced mitophagy in the pathogenesis of Parkinson disease. Autophagy (2009) 1.82
The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol (2008) 1.80
The genetics of Parkinson's syndromes: a critical review. Curr Opin Genet Dev (2009) 1.79
Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov Disord (2008) 1.78
Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol (2008) 1.69
What causes cell death in Parkinson's disease? Ann Neurol (2008) 1.66
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord (2008) 1.61
A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology (1988) 1.57
Is Parkinson's disease a prion disorder? Proc Natl Acad Sci U S A (2009) 1.56
Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology (2005) 1.54
Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord (2007) 1.52
Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol (2006) 1.48
Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol (2008) 1.47
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol (2006) 1.46
Recreational physical activity and risk of Parkinson's disease. Mov Disord (2008) 1.45
Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.41
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain (2009) 1.40
Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci (2009) 1.34
A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. J Neurosci (2008) 1.34
Absence of nigral degeneration in aged parkin/DJ-1/PINK1 triple knockout mice. J Neurochem (2009) 1.34
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci (2008) 1.32
The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov Disord (2008) 1.26
Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology (1999) 1.24
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol (2002) 1.22
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci (2006) 1.19
Parkin and PINK1 mutations in early-onset Parkinson's disease: comprehensive screening in publicly available cases and control. J Med Genet (2009) 1.19
In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener (2008) 1.18
Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol (2008) 1.17
Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord (2008) 1.17
Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cells Dev (2010) 1.15
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis (2007) 1.15
Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem (2008) 1.13
The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Mov Disord (2009) 1.10
Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov Disord (2002) 1.10
Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism Relat Disord (2008) 1.10
Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord (2009) 1.09
Rate of clinical progression in Parkinson's disease. A prospective study. Mov Disord (2007) 1.07
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (2007) 8.10
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol (2006) 5.40
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord (2012) 5.12
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol (2008) 4.73
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. Hum Mol Genet (2010) 3.77
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol (2009) 3.62
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet (2003) 3.51
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord (2006) 3.13
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat Rev Neurosci (2010) 3.05
The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord (2007) 3.04
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron (2002) 2.65
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord (2011) 2.27
Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis (2006) 2.23
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol (2012) 2.20
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids. Arch Neurol (2005) 2.17
Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol (2006) 2.17
Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol (2010) 2.12
Linkage disequilibrium and association of MAPT H1 in Parkinson disease. Am J Hum Genet (2004) 2.10
JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.05
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol (2003) 2.01
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2006) 1.95
Levodopa-induced dyskinesias. Mov Disord (2007) 1.94
Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A (2008) 1.93
The placebo treatments in neurosciences: New insights from clinical and neuroimaging studies. Neurology (2008) 1.92
The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci (2003) 1.92
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord (2011) 1.87
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85
Multiple biological pathways link cognitive lifestyle to protection from dementia. Biol Psychiatry (2011) 1.79
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.78
Analyzing the cost effectiveness of Santiago, Chile's policy of using urban forests to improve air quality. J Environ Manage (2007) 1.76
Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord (2012) 1.76
The subthalamic nucleus is involved in successful inhibition in the stop-signal task: a local field potential study in Parkinson's disease. Exp Neurol (2012) 1.74
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Arch Neurol (2003) 1.74
Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease. Mov Disord (2008) 1.72
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. Proc Natl Acad Sci U S A (2007) 1.71
A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol (2010) 1.70
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord (2013) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest (2010) 1.64
Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol (2003) 1.64
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov Disord (2014) 1.63
Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol (2009) 1.61
Silencing of PINK1 expression affects mitochondrial DNA and oxidative phosphorylation in dopaminergic cells. PLoS One (2009) 1.59
Deep brain stimulation: postoperative issues. Mov Disord (2006) 1.57
Neuropathic features in fragile X premutation carriers. Am J Med Genet A (2007) 1.56
Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol (2002) 1.55
Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation. Mol Cell Biol (2005) 1.55
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery (2002) 1.54
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One (2013) 1.54
Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology (2003) 1.54
Part 1: the history of 19th century neurology and the American Neurological Association. Ann Neurol (2003) 1.54
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain (2014) 1.54
The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord (2010) 1.50
Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol (2003) 1.49
Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol (2005) 1.48
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol (2005) 1.48
Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex (2004) 1.48
Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol (2008) 1.47
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci (2011) 1.45
Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. Mov Disord (2013) 1.44
Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol (2008) 1.43
Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord (2005) 1.41
Pathologically proven frontotemporal dementia presenting with severe amnesia. Brain (2005) 1.41
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One (2011) 1.40
Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol (2005) 1.40
The origins of scientific cinematography and early medical applications. Neurology (2004) 1.39